Updated Price Disclosure Guidelines

By Petrina Smith
Tuesday, 26 November, 2013


An updated version of the Price Disclosure Arrangements Procedural and Operational Guidelines for Expanded and Accelerated Price Disclosure has been published.
The updated Guidelines reflect changes made to the National Health (Pharmaceutical  Benefits) Regulations 1960 in April 2013. According to the Department of Health website, those Regulation changes were made following December 2012 litigation concerning inclusion of de-listed brands in price disclosure calculations.  The Guidelines also provide more information about a number of other matters, including:



  • how to disclose data when the commercial responsibility for a brand passes before the legally responsible person has been changed;

  • calculating new premiums for price disclosure reductions;

  • how price disclosure reductions are applied to new brands listing after the end of a data collection period and before the reduction day;


and

  • how reduced prices are adjusted to take account of any change in pricing quantity for brands of a pharmaceutical item between the end of the data collection period and the reduction day


Find out more at http://www.pbs.gov.au/info/industry/pricing/eapd#Explanatory
Related Articles

New Precision Care Clinic at NSW's Prince of Wales Hospital

The clinic will provide personalised and tailored care for cancer and hopes to facilitate rapid...

Long COVID no different to other post-viral syndromes?

Latest research led by Queensland's Chief Health Officer Dr John Gerrard suggests long COVID...

Open water swimming: identifying and managing SIPE

SIPE occurs when excess fluid accumulates in the lungs, causing acute shortness of breath during...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd